Abstract
Patients receiving TNF-α blockers are exposed to side effects, classified as infectious, immune-related or neoplastic adverse events. Bacterial cellulitis is the predominant cutaneous infectious side effect. Cutaneous non tuberculosis mycobacteriosis or severe herpes zoster have also been reported. Localized and acute, or delayed, generalized hypersensitivity can also occur. Recently, paradoxical cutaneous manifestations have been described, including psoriasis-like eruptions, cutaneous vasculitis or granulomatosus dermatitis. Finally, an increased risk for skin cancers, including carcinoma and melanoma, has been suggested in patients receiving TNF-α blockers, requiring the development of preventive strategies. In each case, skin involvement can be in the front line and help to reveal more severe systemic involvement, underlying the need for a careful skin examination in patients treated with TNF-α blockers.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
